Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial.
Manolakopoulos S, Avgerinos A, Vlachogiannakos J, Armonis A, Viazis N, Papadimitriou N, Mathou N, Stefanidis G, Rekoumis G, Vienna E, Tzourmakliotis D, Raptis SA. Manolakopoulos S, et al. Among authors: vlachogiannakos j. Gastrointest Endosc. 2002 Apr;55(4):470-5. doi: 10.1067/mge.2002.122614. Gastrointest Endosc. 2002. PMID: 11923756 Clinical Trial.
Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: a prospective, randomized, placebo-controlled trial.
Avgerinos A, Sgouros S, Viazis N, Vlachogiannakos J, Papaxoinis K, Bergele C, Sklavos P, Raptis SA. Avgerinos A, et al. Among authors: vlachogiannakos j. Scand J Gastroenterol. 2005 May;40(5):515-22. doi: 10.1080/00365520510015458. Scand J Gastroenterol. 2005. PMID: 16036503 Clinical Trial.
DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Papatheodoridis GV, et al. Among authors: vlachogiannakos j. Antivir Ther. 2018;23(8):677-685. doi: 10.3851/IMP3256. Antivir Ther. 2018. PMID: 30044765
Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Papatheodoridis GV, et al. Among authors: vlachogiannakos j. Antivir Ther. 2018;23(8):711. doi: 10.3851/IMP3261. Antivir Ther. 2018. PMID: 30091421 No abstract available.
Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis.
Kranidioti H, Chatzievagelinou C, Protopapas A, Papatheodoridi M, Zisimopoulos K, Evangelidou E, Antonakaki P, Vlachogiannakos J, Triantos C, Elefsiniotis I, Goulis J, Mela M, Anagnostou O, Tsoulas C, Deutsch M, Papatheodoridis G, Manolakopoulos S. Kranidioti H, et al. Among authors: vlachogiannakos j. Ann Gastroenterol. 2018 Sep-Oct;31(5):598-603. doi: 10.20524/aog.2018.0293. Epub 2018 Jul 19. Ann Gastroenterol. 2018. PMID: 30174397 Free PMC article.
107 results